Scarica l'app Stockscreener
17.32
1.82%
0.31
Dopo l'orario di chiusura:
17.20
-0.12
-0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$17.01
Aprire:
$17.02
Volume 24 ore:
1.62M
Relative Volume:
1.91
Capitalizzazione di mercato:
$527.67M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-3.3762
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-1.31%
1M Prestazione:
+15.16%
6M Prestazione:
+18.87%
1 anno Prestazione:
-69.39%
Intervallo 1D:
$16.88
$17.46
Intervallo di 1 settimana:
$16.31
$18.42
Portata 52W:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
17.32 | 518.23M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
ExodusPoint Capital Management, LP's Strategic Acquisition of Keros Therapeutics Inc. Shares - GuruFocus
Latham & Watkins Advises on Keros Therapeutics, Inc.’s US$194.4 Million Tender Offer - Latham & Watkins LLP
The Technical Signals Behind (KROS) That Institutions Follow - news.stocktradersdaily.com
Keros Therapeutics announces final results of tender offer - MarketScreener
[SC TO-I/A] Keros Therapeutics, Inc. Amended Issuer Tender Offer | KROS SEC FilingForm SC TO-I/A - Stock Titan
Keros Therapeutics (Nasdaq: KROS) completes $194M tender offer, buying 35.9% of shares - Stock Titan
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownHere's Why - MarketBeat
Is Keros Therapeutics Inc. stock reversal real or fakeWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Keros Therapeutics reports oversubscribed $194.4 million tender offer By Investing.com - Investing.com Nigeria
Can Keros Therapeutics Inc. stock maintain operating margins2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Keros to Repurchase 11 Million Shares in Oversubscribed Tender Offer - MarketScreener
Keros Therapeutics Reports Third Quarter 2025 Financial Results - Sahm
Keros Therapeutics reports oversubscribed $194.4 million tender offer - Investing.com
Keros Therapeutics Announces Preliminary Results of Tender Offer - The Manila Times
Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
How to manage a losing position in Keros Therapeutics Inc.Portfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
How to recover losses in Keros Therapeutics Inc. stockJuly 2025 Price Swings & Accurate Trade Setup Notifications - newser.com
Los Angeles Capital Management LLC Purchases New Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Is Keros Therapeutics Inc. stock attractive for income investors2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Will Keros Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Summary & Daily Chart Pattern Signals - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Will Keros Therapeutics Inc. price bounce be sustainable2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Evaluating Keros Therapeutics Inc. with trendline analysisEntry Point & Short-Term Trading Opportunity Alerts - newser.com
Can volume confirm reversal in Keros Therapeutics Inc.July 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Will Keros Therapeutics Inc. stock return to pre crisis levelsJuly 2025 Short Interest & Weekly Top Gainers Alerts - newser.com
Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer - MarketBeat
Oppenheimer Reiterates Keros Therapeutics (KROS) Outperform Recommendation - Nasdaq
Oppenheimer Adjusts Keros Therapeutics Price Target to $27 From $23, Maintains Outperform Rating - MarketScreener
Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00 - MarketBeat
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - MSN
Wells Fargo Maintains Keros Therapeutics (KROS) Overweight Recommendation - Nasdaq
KROS: Wells Fargo Lowers Price Target to $23, Maintains Overweig - GuruFocus
KROS vs. ARGX: Which Stock Is the Better Value Option? - MSN
Keros Therapeutics, Inc. : Wells Fargo Cuts T - 富途牛牛
Keros Therapeutics Drives Nasdaq Composite Momentum In Medicine - Kalkine Media
How interest rate cuts could boost Keros Therapeutics Inc. stockDay Trade & AI Enhanced Execution Alerts - newser.com
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Keros Therapeutics Inc Azioni (KROS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 15 '25 |
Sale |
17.75 |
5,389,264 |
95,659,436 |
0 |
0.53%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):